Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBNX NASDAQ:EMBC NASDAQ:KRMD NASDAQ:SIBN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$17.05+0.9%$15.14$8.89▼$24.50$734.21MN/A784,221 shs892,018 shsEMBCEmbecta$14.38+4.0%$10.96$9.20▼$21.48$808.85M1.08717,430 shs883,795 shsKRMDKORU Medical Systems$4.38+6.6%$3.61$1.86▼$5.05$190.03M0.47127,979 shs169,216 shsSIBNSiBone$16.39+4.8%$17.06$11.70▼$20.05$674.72M0.91509,321 shs333,628 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics+10.39%+1.08%+12.90%+17.05%+1,688,999,900.00%EMBCEmbecta-0.43%-0.29%+29.37%+29.01%+2.98%KRMDKORU Medical Systems-0.96%-0.24%+19.83%+54.51%+85.97%SIBNSiBone+0.64%+2.22%-8.86%-14.91%+3.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBNXBeta Bionics2.6845 of 5 stars4.40.00.00.02.50.80.0EMBCEmbecta4.8469 of 5 stars3.23.03.30.04.03.33.8KRMDKORU Medical Systems1.2219 of 5 stars1.52.00.00.02.62.50.6SIBNSiBone4.1855 of 5 stars3.54.00.03.31.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBNXBeta Bionics 2.75Moderate Buy$22.5632.29% UpsideEMBCEmbecta 2.33Hold$19.0032.13% UpsideKRMDKORU Medical Systems 3.00Buy$4.635.59% UpsideSIBNSiBone 3.00Buy$23.6744.40% UpsideCurrent Analyst Ratings BreakdownLatest KRMD, EMBC, SIBN, and BBNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/11/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$25.008/5/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.007/30/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $21.007/30/2025BBNXBeta BionicsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetNeutral ➝ Neutral$15.00 ➝ $17.007/16/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$13.00 ➝ $12.006/16/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$26.006/12/2025BBNXBeta BionicsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$30.005/30/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$16.005/30/2025BBNXBeta BionicsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.005/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.00(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBNXBeta Bionics$65.12M11.38N/AN/A$6.94 per share2.46EMBCEmbecta$1.12B0.75$3.47 per share4.15($11.45) per share-1.26KRMDKORU Medical Systems$33.65M6.02N/AN/A$0.36 per share12.17SIBNSiBone$167.18M4.23N/AN/A$3.95 per share4.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBNXBeta Bionics-$54.76MN/A0.00∞N/AN/AN/AN/AN/AEMBCEmbecta$78.30M$1.4310.064.680.777.58%-23.40%14.46%N/AKRMDKORU Medical Systems-$6.07M-$0.09N/AN/AN/A-12.24%-26.77%-16.81%N/ASIBNSiBone-$30.91M-$0.56N/AN/AN/A-12.83%-14.20%-10.38%N/ALatest KRMD, EMBC, SIBN, and BBNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q3 2025EMBCEmbecta$0.7720$1.12+$0.3480$0.78$278.15 million$295.50 million8/6/2025Q2 2025KRMDKORU Medical Systems-$0.03$0.01+$0.04N/A$9.46 million$10.20 million8/4/2025Q2 2025SIBNSiBone-$0.19-$0.14+$0.05-$0.14$48.12 million$48.63 million7/29/2025Q2 2025BBNXBeta Bionics-$0.51-$0.39+$0.12-$0.39$19.73 million$23.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBNXBeta BionicsN/AN/AN/AN/AN/AEMBCEmbecta$0.604.17%N/A41.96%N/AKRMDKORU Medical SystemsN/AN/AN/AN/AN/ASIBNSiBoneN/AN/AN/AN/AN/ALatest KRMD, EMBC, SIBN, and BBNX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/6/2025EMBCEmbectaquarterly$0.155.79%8/29/20258/29/20259/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBNXBeta BionicsN/A14.6813.79EMBCEmbectaN/A2.471.78KRMDKORU Medical Systems0.012.912.25SIBNSiBone0.218.387.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBNXBeta BionicsN/AEMBCEmbecta93.83%KRMDKORU Medical Systems58.60%SIBNSiBone98.11%Insider OwnershipCompanyInsider OwnershipBBNXBeta BionicsN/AEMBCEmbecta0.42%KRMDKORU Medical Systems20.60%SIBNSiBone4.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBNXBeta Bionics29443.47 millionN/AN/AEMBCEmbecta2,10058.49 million58.24 millionOptionableKRMDKORU Medical Systems8046.24 million36.71 millionOptionableSIBNSiBone35043.14 million41.42 millionOptionableKRMD, EMBC, SIBN, and BBNX HeadlinesRecent News About These Companies1,326,100 Shares in SiBone $SIBN Acquired by Nuveen LLCAugust 22 at 3:47 AM | marketbeat.comSiBone (NASDAQ:SIBN) SVP Sells $52,065.56 in StockAugust 21 at 8:54 AM | insidertrades.comTocqueville Asset Management L.P. Has $3.58 Million Stake in SiBone (NASDAQ:SIBN)August 19 at 6:04 AM | marketbeat.comSiBone (NASDAQ:SIBN) Director John Gordon Freund Sells 12,132 SharesAugust 12, 2025 | marketbeat.comInsider Selling: SiBone (NASDAQ:SIBN) Director Sells 12,132 Shares of StockAugust 12, 2025 | insidertrades.comSiBone (NASDAQ:SIBN) Stock Rating Lowered by Wall Street ZenAugust 10, 2025 | marketbeat.comFY2025 EPS Estimates for SiBone Boosted by Cantor FitzgeraldAugust 9, 2025 | marketbeat.comSiBone (NASDAQ:SIBN) Shares Down 13.1% - Here's What HappenedAugust 6, 2025 | marketbeat.comSiBone (NASDAQ:SIBN) Earns "Overweight" Rating from Cantor FitzgeraldAugust 6, 2025 | marketbeat.comSiBone (NASDAQ:SIBN) Issues Quarterly Earnings ResultsAugust 5, 2025 | marketbeat.comSI-Bone Reports Strong Q2 2025 Financial ResultsAugust 5, 2025 | msn.comSI-BONE, Inc. (SIBN) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comSI-BONE, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 4, 2025 | seekingalpha.comSi-Bone (SIBN) Reports Q2 Loss, Beats Revenue EstimatesAugust 4, 2025 | zacks.comSI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 GuidanceAugust 4, 2025 | globenewswire.comUniversal Beteiligungs und Servicegesellschaft mbH Acquires New Holdings in SiBone (NASDAQ:SIBN)August 3, 2025 | marketbeat.comSI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025July 29, 2025 | globenewswire.comSiBone (SIBN) Projected to Post Quarterly Earnings on MondayJuly 28, 2025 | marketbeat.comVictory Capital Management Inc. Raises Stock Holdings in SiBone (NASDAQ:SIBN)July 25, 2025 | marketbeat.comLegato Capital Management LLC Acquires 36,649 Shares of SiBone (NASDAQ:SIBN)July 24, 2025 | marketbeat.comSI-BONE To Report Second Quarter 2025 Financial Results on August 4, 2025July 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKRMD, EMBC, SIBN, and BBNX Company DescriptionsBeta Bionics NASDAQ:BBNX$17.05 +0.16 (+0.95%) As of 04:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Embecta NASDAQ:EMBC$14.38 +0.55 (+3.98%) Closing price 04:00 PM EasternExtended Trading$14.38 +0.00 (+0.03%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.KORU Medical Systems NASDAQ:KRMD$4.38 +0.27 (+6.57%) Closing price 04:00 PM EasternExtended Trading$4.38 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.SiBone NASDAQ:SIBN$16.39 +0.75 (+4.80%) Closing price 04:00 PM EasternExtended Trading$16.05 -0.34 (-2.07%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot 3 Reasons Salesforce Is a Bargain Right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.